Company / Depreciation & Amortization
NovoCure Ltd Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$14.7M
FY2025
5-year range
$8.5M / $14.7M
FY2021-FY2025
Trend
+30.4%
vs FY2024
Sector context
#110 of 141
Health Care
What the data says
NovoCure Ltd's depreciation & amortization of $15M is lower than 78% of companies in the Health Care sector (FY2025). Depreciation & Amortization has increased for 4 consecutive years, from $8M in FY2021 to $15M in FY2025.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of +10.2%.
Increased from $11M to $15M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +17.0%
- 5-Year CAGR
- +10.2%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 141This company $14.7M Sector average $344.6M
▼
-95.7% below sector average
Key checks
Key Insights
- NovoCure Ltd's depreciation & amortization has grown for 4 consecutive years.
- 5-year CAGR of +10.2%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 30.4% year-over-year.
- Ranks #110 out of 141 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.7M | +30.4% |
| FY2024 | $11.2M | +2.4% |
| FY2023 | $11.0M | +19.9% |
| FY2022 | $9.2M | +8.2% |
| FY2021 | $8.5M | -6.1% |
| FY2020 | $9.0M | +17.3% |
| FY2019 | $7.7M | +35.8% |
| FY2018 | $5.7M | +79.3% |
| FY2017 | $3.2M | +60.7% |
| FY2016 | $2.0M | +61.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026